Implications of Vancomycin Degradation Products on Therapeutic Drug Monitoring in Patients with End‐Stage Renal Disease
暂无分享,去创建一个
[1] D. Thompson,et al. Historical Yearly Usage of Vancomycin , 1998, Antimicrobial Agents and Chemotherapy.
[2] T. Johns,et al. Laboratory guidelines for monitoring of antimicrobial drugs , 1998 .
[3] W. Petros,et al. New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease. , 1998, Therapeutic Drug Monitoring.
[4] I. Ieiri,et al. Instability of standard calibrators may be involved in overestimating vancomycin concentrations determined by fluorescence polarization immunoassay. , 1996, Therapeutic drug monitoring.
[5] N. Saunders. Vancomycin administration and monitoring reappraisal. , 1995, The Journal of antimicrobial chemotherapy.
[6] R. Moellering. Monitoring serum vancomycin levels: climbing the mountain because it is there? , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] P. Lietman,et al. Serum vancomycin concentrations: reappraisal of their clinical value. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] B. Ackerman,et al. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response , 1992, Antimicrobial Agents and Chemotherapy.
[9] G. Hortin,et al. Cross-reactivity of a vancomycin degradation product in three immunoassays of vancomycin. , 1991, Clinical chemistry.
[10] K. Rodvold,et al. An Updated Comparison of Drug Dosing Methods , 1991, Clinical pharmacokinetics.
[11] K. Rodvold,et al. An Updated Comparison of Drug Dosing Methods , 1991, Clinical pharmacokinetics.
[12] M. Hu,et al. Measurement of Vancomycin in Renally Impaired Patient Samples Using a New High‐Performance Liquid Chromatography Method with Vitamin B12 Internal Standard: Comparison of High‐Performance Liquid Chromatography, Emit, and Fluorescence Polarization Immunoassay Methods , 1990, Therapeutic drug monitoring.
[13] W. Peetermans,et al. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection , 1990, Antimicrobial Agents and Chemotherapy.
[14] J. M. Lanao,et al. Effect of renal impairment on distribution of ofloxacin. , 1990 .
[15] K. Chan,et al. Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. , 1989, Therapeutic drug monitoring.
[16] G. Horowitz,et al. Clinical performance of the EMIT vancomycin assay. , 1989, Clinical chemistry.
[17] R. Finch,et al. The in-vitro degradation at 37°C of vancomycin in serum, CAPD fluid and phosphate-buffered saline , 1988 .
[18] J. Rotschafer,et al. Vancomycin pharmacokinetics in patients with various degrees of renal function , 1988, Antimicrobial Agents and Chemotherapy.
[19] J. Flandrois,et al. Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus , 1988, Antimicrobial Agents and Chemotherapy.
[20] G. Morse,et al. Overestimation of Vancomycin Concentrations Utilizing Fluorescence Polarization Immunoassay in Patients on Peritoneal Dialysis , 1987, Therapeutic drug monitoring.
[21] P. Murray,et al. Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay , 1984, Journal of clinical microbiology.
[22] R. Hay,et al. Laboratory methods for flucytosine (5-fluorocytosine) , 1984 .
[23] C. Harris,et al. VANCOMYCIN: STRUCTURE AND TRANSFORMATION TO CDP-I , 1983 .
[24] J. Rotschafer,et al. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations , 1982, Antimicrobial Agents and Chemotherapy.
[25] D J Greenblatt,et al. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. , 1981, Annals of internal medicine.
[26] J. Geraci,et al. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report. , 1958, Proceedings of the staff meetings. Mayo Clinic.
[27] M. K. Scott,et al. Falsely elevated serum vancomycin concentrations in hemodialysis patients. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[28] J. Rotschafer,et al. Routine monitoring of serum vancomycin concentrations: can waiting be justified? , 1987, Clinical pharmacy.
[29] R. Griffith. Vancomycin use--an historical review. , 1984, The Journal of antimicrobial chemotherapy.
[30] F. J. Marshall. STRUCTURE STUDIES ON VANCOMYCIN. , 1965, Journal of medicinal chemistry.